Tag: Novartis
Hopeful cancer drug: Novartis swallows Morphosys for 2.7 billion
Hopeful cancer drug Novartis swallows Morphosys for 2.7 billion February 6, 2024, 12:02 a.m Listen to article This audio version was artificially generated. More info | Send feedback The Swiss…
Novartis in advanced talks to acquire MorphoSys
Published on 02/05/2024 at 6:21 p.m. Photo credit © Reuters (Reuters) – Drugmaker Novartis is in advanced…
Novartis apparently in talks: Morphosys takes off with rumors of takeover
Novartis apparently in talks Morphosys take off with takeover rumors February 5, 2024, 6:08 p.m Listen to article This audio version was artificially generated. More info | Send feedback The…
Novartis: result of a phase III trial with Lutathera
(CercleFinance.com) – Novartis Lutathera® significantly reduced the risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors. In the phase III NETTER-2…
Novartis: Results of a phase III trial with Lutathera
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Market: Novartis in advanced discussions for the acquisition of Cytokinetics
(Reuters) – Swiss laboratory Novartis is in advanced discussions to acquire Cytokinetics in a transaction that could value the American biopharmaceutical company at more than $10 billion (9.14 billion euros),…
Novartis: Positive phase III data in leukemia
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Novartis: positive phase III data in leukemia
(CercleFinance.com) – Novartis announces positive results from the primary analysis of ASC4FIRST, a pivotal phase III trial in the treatment of newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia…
Novartis: FDA approves new production unit
(CercleFinance.com) – Novartis announced on Friday that the US Food and Drug Administration (FDA) had approved a new pharmaceutical production site for Pluvicto, its new treatment for prostate cancer, based…
Novartis: FDA approves new production unit
(CercleFinance.com) – Novartis announced on Friday that the US Food and Drug Administration (FDA) had approved a new pharmaceutical production site for Pluvicto, its new treatment for prostate cancer, based…
Novartis: new favorable data in PNH
(CercleFinance.com) – Novartis on Monday unveiled new positive data over a period of 48 weeks as part of its phase III clinical study conducted in patients with paroxysmal nocturnal hemoglobinuria…
Novartis: presents data from more than 100 trials
(CercleFinance.com) – Novartis presents important data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH trade shows Novartis will present data from more than 100 trials across its breast…